GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (BSP:I1LM34) » Definitions » Cyclically Adjusted Price-to-FCF

Illumina (BSP:I1LM34) Cyclically Adjusted Price-to-FCF : 27.07 (As of May. 31, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Illumina Cyclically Adjusted Price-to-FCF?

As of today (2024-05-31), Illumina's current share price is R$108.57. Illumina's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was R$4.01. Illumina's Cyclically Adjusted Price-to-FCF for today is 27.07.

The historical rank and industry rank for Illumina's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BSP:I1LM34' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 22.25   Med: 97.58   Max: 212.26
Current: 23.26

During the past years, Illumina's highest Cyclically Adjusted Price-to-FCF was 212.26. The lowest was 22.25. And the median was 97.58.

BSP:I1LM34's Cyclically Adjusted Price-to-FCF is ranked better than
65.08% of 63 companies
in the Medical Diagnostics & Research industry
Industry Median: 35.56 vs BSP:I1LM34: 23.26

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Illumina's adjusted free cash flow per share data for the three months ended in Mar. 2024 was R$0.257. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is R$4.01 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Illumina Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Illumina's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Cyclically Adjusted Price-to-FCF Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.85 94.06 90.62 47.92 32.72

Illumina Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.43 44.56 32.35 32.72 31.62

Competitive Comparison of Illumina's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Illumina's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Illumina's Cyclically Adjusted Price-to-FCF falls into.



Illumina Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Illumina's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=108.57/4.01
=27.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Illumina's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.257/131.7762*131.7762
=0.257

Current CPI (Mar. 2024) = 131.7762.

Illumina Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.464 100.560 0.608
201409 0.351 100.428 0.461
201412 0.271 99.070 0.360
201503 0.128 99.621 0.169
201506 0.542 100.684 0.709
201509 0.790 100.392 1.037
201512 1.730 99.792 2.284
201603 0.230 100.470 0.302
201606 0.805 101.688 1.043
201609 0.475 101.861 0.615
201612 0.816 101.863 1.056
201703 0.362 102.862 0.464
201706 0.489 103.349 0.624
201709 0.639 104.136 0.809
201712 0.971 104.011 1.230
201803 0.731 105.290 0.915
201806 1.111 106.317 1.377
201809 1.257 106.507 1.555
201812 1.201 105.998 1.493
201903 0.732 107.251 0.899
201906 0.497 108.070 0.606
201909 1.214 108.329 1.477
201912 2.127 108.420 2.585
202003 1.591 108.902 1.925
202006 1.409 108.767 1.707
202009 0.766 109.815 0.919
202012 2.392 109.897 2.868
202103 1.840 111.754 2.170
202106 1.430 114.631 1.644
202109 -2.236 115.734 -2.546
202112 1.527 117.630 1.711
202203 0.695 121.301 0.755
202206 0.347 125.017 0.366
202209 -1.991 125.227 -2.095
202212 0.394 125.222 0.415
202303 -0.284 127.348 -0.294
202306 0.356 128.729 0.364
202309 0.588 129.860 0.597
202312 1.073 129.419 1.093
202403 0.257 131.776 0.257

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Illumina  (BSP:I1LM34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Illumina Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Illumina's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (BSP:I1LM34) Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina (BSP:I1LM34) Headlines

No Headlines